CVR number 36460598
Industry 812300

BioSan ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  18.2% 19.2% 18.7% 22.9% 23.5%  
Credit score (0-100)  9 6 6 3 3  
Credit rating  B B B B B  
Credit limit (kDKK)  0.0 -0.0 0.0 -0.0 -0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  97.0 315 617 122 288  
EBITDA  97.0 86.0 250 -56.0 205  
EBIT  97.0 2.0 94.0 -231 18.8  
Pre-tax profit (PTP)  67.0 -36.0 12.0 -262.0 5.0  
Net earnings  51.0 -108.0 23.0 -263.0 5.0  
Pre-tax profit without non-rec. items  67.0 -36.0 12.0 -262 5.0  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 745 634 604 449  
Shareholders equity total  65.0 -278 -254 -518 -513  
Interest-bearing liabilities  0.0 314 192 192 192  
Balance sheet total (assets)  890 2,110 1,826 1,066 1,471  
Net Debt  -27.0 279 18.0 145 55.6  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  97.0 315 617 122 288  
Gross profit growth  592.9% 224.7% 95.9% -80.2% 135.7%  
Employees  1 2 2 2 2  
Employee growth %  0.0% 100.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  890 2,110 1,826 1,066 1,471  
Balance sheet change%  -66.1% 137.1% -13.5% -41.6% 38.0%  
Added value  97.0 86.0 250.0 -75.0 204.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 661 -267 -205 -341  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 -1.0 1.0  

Profitability 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 0.6% 15.2% -189.3% 6.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  5.5% 0.2% 4.3% -13.0% 1.1%  
ROI %  245.6% 2.3% 49.5% -124.0% 9.8%  
ROE %  129.1% -9.9% 1.2% -18.2% 0.4%  

Solidity 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  7.3% -10.6% -12.2% -32.7% -25.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -27.8% 324.4% 7.2% -258.9% 27.1%  
Gearing %  0.0% -112.9% -75.6% -37.1% -37.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 24.8% 32.8% 12.5% 7.2%  

Liquidity 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.9 0.4 0.4 0.2 0.5  
Current Ratio  1.1 0.6 0.6 0.3 0.5  
Cash and cash equivalent  27.0 35.0 174.0 47.0 136.5  

Capital use efficiency 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  56.0 -1,037.0 -921.0 -1,155.0 -995.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  97 43 125 -38 102  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  97 43 125 -28 102  
EBIT / employee  97 1 47 -116 9  
Net earnings / employee  51 -54 12 -132 2